Form 4: Phathom Pharmaceuticals COO Sells Shares to Cover Tax Obligations

Azmi Nabulsi, Chief Operating Officer of Phathom Pharmaceuticals, sold 1,118 shares of common stock to cover tax obligations related to the settlement of restricted stock units.

Summary

• Azmi Nabulsi, the Chief Operating Officer of Phathom Pharmaceuticals, sold 1,118 shares of the company's common stock on December 19, 2024.
• The sale was executed at a price of $8 per share.
• This transaction was conducted to satisfy tax withholding obligations arising from the settlement of restricted stock units.
• Following the transaction, Mr. Nabulsi directly owns 239,303 shares of common stock.
• He also indirectly owns 3,578.93 shares through a 401(k) and 785,700 shares through a trust.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, with no indication of positive or negative sentiment.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax liabilities when restricted stock units vest.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across the pharmaceutical industry.
• Many companies use restricted stock units as part of their compensation packages, leading to similar transactions by executives at other firms.
• The sale of 1,118 shares is relatively small compared to the total holdings of the executive, which is typical for these types of transactions.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a small sale by an executive to cover tax obligations.

Key Dates

Keywords

Phathom Pharmaceuticals, Azmi Nabulsi, stock sale, insider trading, Form 4, tax obligations, restricted stock units, executive compensation